| Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly require the presence of αβT cells that recognize tumour neoantigens, and are therefore primarily restricted to tumours with high mutational load. Approaches that could address this limitation by engineering αβT cells, such as chimeric antigen receptor T (CAR T) cells, are being investigated intensively , but these approaches have other issues, such as a scarcity of appropriate targets for CAR T cells in solid tumours. Consequently , there is renewed interest among translational researchers and commercial partners in the therapeutic use of γδT cells and their receptors. Overall, γδT cells display potent cytotoxicity , which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. In this Review , we discuss the challenges and opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.
T cell responses to a broad variety of pathogens as well as to cancer cells are mediated through the diversity of their individual αβ or γδ T cell receptors. Although αβ and γδ T cells originate from common thymic precursors, the biological roles and molecular understanding of these two subsets differ substantially. Activation of αβT cells depends on the expression of peptides derived from proteins that are expressed in a cell and then presented in a defined HLA molecule. Usually, αβT cells are tolerant towards self-peptides but recognize major changes in cell protein composition that occur either during infection (through the expression of novel viral proteins) or during carcinogenesis. Owing to the fact that each individual has their own set of HLA molecules, the αβT cell immune systems cannot easily be transferred between individuals, except if two individuals have a precise match of all HLA molecules. By contrast, most of the time, γδT cells do not rely on the recognition of classic HLA molecules, and sensing of infection or cancer depends on more ubiquitous changes observed across many individuals. Therefore, γδT cell immune systems can be transferred more easily between individuals. As γδT cells rapidly recognize ubiquitous changes, γδT cells are considered to partially belong to the first line of immune defence (the innate immune system), but they also have the possibility to create immunological memory and therefore are also partially adaptive 1 . In contrast to the well-characterized biological role of αβT cells in cancer immune surveillance, the protective role of γδT cells during tumour development has only been increasingly reported over the past two decades. The seminal demonstration of this concept was esta blished using γδT cell-deficient mice, in which γδT cells could inhibit the early development of cutaneous squamous cell carcinoma induced by skin administration of chemical mutagens 2 . Since then, many studies in mice have confirmed the protective role of γδT cells, either in transplantable models or in spontaneous cancer models (reviewed in ref. 3 ). The antitumour function of γδT cells is most generally associated with their production of both interferon γ (IFNγ) and tumour necrosis factor (TNF), and/or with their cytotoxic potential, but studies have also reported the importance of IL-17-producing γδT cells, especially when they act in concert with immuno genic cell death-inducing chemotherapeutic drugs 4 . Whether γδT cells that operate within the tumour are cells that infiltrate from the circulation or are resident cells that expand within the transformed tissue is still elusive. Nonetheless, the expansion of tissue-resident innate-like lymphocytes -γδT cells among themhas been observed in early spontaneous cancer lesions in mammary (MMTV-PyMT) and prostate (Tramp) Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies mouse models 5 . These immune cells displayed a unique phenotype characterized by eradication of tumour cells through cytotoxic granule release, IL-15 dependence for expansion in response to cell transformation and expression of NK1.1 (a marker usually expressed on natural killer (NK) cells), collagen-binding molecule CD49a and the adhesion molecule CD103.
The correlation of levels of tumour-infiltrating lymphocyte γδT cells with clinical outcomes in patients, which varies according to cancer type, further confirms the role of γδT cells in cancer immune surveillance. Tumour-infiltrating γδT cells have been associated with good prognoses in patients with melanoma 6 and in gastric cancer 7 . However, different functional subsets of γδT cells might have different functions within tumours, and even the same subset can undergo different functional polarizations. For example, in a transcriptomic analysis of tumours from more than 500 patients with colorectal cancer (CRC), the 5-year disease-free survival pro bability was significantly higher when the number of tumour-infiltrating γδT cells was high 8 . However, this observation markedly contrasted with the protumour role of IL-17-producing γδT cells reported by Wu et al. 9 . This discrepancy in the prognostic impact of γδT cells in patients with CRC may be explained by the γδT cell subsets analysed in the two studies: the transcriptomic signature used in Dieli's study was established from Vγ9Vδ2 T cells, the main type of circulating human γδT cells, whereas the IL-17-producing γδT cells in the latter study were Vδ1 + T cells. Analysis of γδT cells in situ is further complicated by technical challenges. As an alternative, γδT cell composition in tumours can be inferred from transcriptomic signatures analysed in microarrays. Using the cell-type identification by estimating relative subsets of known RNA transcripts (CIBERSORT) algorithm, an extensive analysis of immune subset transcriptomic signatures from 18,000 tumours revealed that γδT cells is the immune subset most significantly associated with a favourable prognosis 10 . The capacity of CIBERSORT to recognize all γδT lymphocytes accurately was recently revisited, and as a result the Vγ9Vδ2 gene signature was improved in order to allow a better separation of Vγ9Vδ2 T cells from αβT and NK cells 11 . Abundance of tumour-infiltrating Vγ9Vδ2 T cells correlated neither with that of αβT cells nor with the mutational load in a panel of tumours analysed with this new signature. These results are consistent with γδT cell independence of major histocompatibility complex (MHC) presentation, confirm their non-redundant function with αβT cells and underline why they are of interest for therapy in poorly mutated tumours (for a review, see also 12 ). Newly developed single-cell techno logies will provide further insight into the biology of tumour-infiltrating γδT cells 13 .
High circulating levels of γδT cells have also been associated with reduced cancer risk and improved 5-year disease-free and overall survival after bone marrow transplantation in patients with acute leukaemia 14 . Elevated levels of γδT cells were also associated with a lower incidence of infections after haematopoietic stem cell transplantation in paediatric patients, as a result of the dual antiviral and antitumoural reactivity of these cells 15 .
Cytomegalovirus (CMV) infection or reactivation can elicit a response of non-Vγ9Vδ2 γδT cells endowed with a dual reactivity against CMV-infected cells, leukaemia 16 and other tumour cells 17, 18 . However, the transplantation technique can affect the immune reconstitution of different immune subsets and clinical outcomes 19 . These encouraging observations made in allogeneic stem cell transplantation have inspired the use of mobilized peripheral stem cells, in which only αβT cells (instead of all T cells) were depleted, to prevent MHC-dependent allo-reactivity, and only γδT cells were transferred back to the patient during infusion of the stem cell product 20 . Such settings reduced graft-versus-host disease -a lethal complication after stem cell transplantation, usually mainly mediated through αβT cells -improved γδT cell reconstitution post-transplantation and were associated with favourable clinical outcomes 20 . In kidney transplant recipients, a high percentage of non-Vγ9Vδ2 γδT cells in blood was associated with reduced risk of secondary skin cancers in immunosuppressed patients 21 . This was observed only in patients infected with CMV, in line with the suggestion that non-Vγ9Vδ2 γδT cells indeed cross-react between infected cells and tumours 17, 18, 22 .
In this Review, we discuss novel insights into the understanding of γδT cell biology, in terms of repertoire development and receptor diversity. We analyse why previous attempts to use γδT cells to treat cancer have failed in the clinic, and define novel paths for their potential successful clinical translation. Finally, we also provide examples of how such new insights are currently being translated from academia and also new commercial partners into therapeutic products.
Molecular and functional diversity
Inspired by the indications in the past decade that γδT cells are key players in cancer immune surveillance, multi ple clinical studies have explored the in vitro expansion or the adoptive transfer of Vγ9Vδ2 T cells as a therapeutic strategy outside the context of a transplantation setting 23 . Clinical strategies to date have made use of chemical compounds that either boost or mimic the expression of phosphoantigens (which are intracellular metabolites of the mevalonate pathway that can also be derived from bacteria or viruses) to stimulate Vγ9Vδ2 T cells directly. Some strategies have used aminobisphosphonates (such as pamidronate and zoledronate) or synthetic phosphoantigen analogues, including bromohydrin pyrophosphate (BrHPP) and 2-methyl-3-butenyl-1-pyro phosphate (2M3B1PP), which enhance the expression of endogenous phosphoantigens both on the side of antigenpresenting cells -such as monocytes -and on the tumour side ( fig. 1 ) [24] [25] [26] .
Multiple clinical trials have attempted in vivo stimulation of autologous Vγ9Vδ2 T cells in patients by using such aminobisphosphonates, and although no severe toxicity was observed, no substantial antitumoural activity was reported, either [27] [28] [29] [30] [31] [32] [33] [34] [35] . Lack of efficacy was also reported in clinical trials that explored the transfer of ex vivo-expanded autologous or allogeneic Vγ9Vδ2 T cells, alone or in combination with stimulating agents [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] (Table 1) . Thus, the activation or transfer of
Vγ9Vδ2 T cells
The main circulating human γδT cells, in which their γδ T cell receptor (TCr) heterodimer is built by a TCrγ chain that uses a Vγ9 segment and a TCrδ chain using the variable (V) segment Vδ2. Vγ9Vδ2 T cells display a relatively limited diversity of their individually rearranged TCr sequences, and are therefore regarded as semi-invariant.
Vδ1 + T cells a subset of human γδT cells in which their T cell receptor (TCr) uses a Vδ1 segment for its TCrδ chain. TCrδ sequences of Vδ1 + T cells are more diverse than those of Vγ9Vδ2 T cells, and the repertoire of Vδ1 + T cells is further expanded by pairing with different TCrγ chains (using Vγ2, 3,4,5,8, and non-invariant Vγ9 segments). Vδ1 + T cells have been reported to recognize a wide range of cancer cells.
non-Vγ9Vδ2 γδT cells
all human γδT cells except Vγ9Vδ2 γδT cells, including TCrδ chain 1 or 3 to 8, and any Vγ chains (Vγ2, 3, 4, 5, 8, 9) .
Phosphoantigens intracellular metabolites of the mevalonate pathway, such as isopentenyl pyrophosphate (iPP), or metabolites derived from the mevalonate-independent 1-deoxyd-xylulose 5-phosphate (DOXP) pathway in bacteria or parasites. (e)-4hydroxy-3-methyl-but-2-enyl pyrophosphate (HMbPP) is produced by several bacteria and parasites and is the most powerful stimulant for Vγ9Vδ2 T cells. also, synthetic phosphoantigens have been reported, such as bromohydrin pyrophosphate (brHPP) and 2-methyl-3-butenyl-1pyrophosphate (2M3b1PP).
Aminobisphosphonates
Metabolites such as pamidronate or zoledronate that partially block the natural mevalonate pathway after the production of isopentenyl pyrophosphate (iPP), through inhibiting farnesyl pyrophosphate synthase, and thereby increase iPP levels. aminobisphosphonates have been used in daily clinical practice for decades -for example, in patients with multiple myeloma -to stabilize bone formation, mainly because of their inhibitory effect on osteoclasts.
www.nature.com/nrd 170 | march 2020 | volume 19 polyclonal γδT cells outside the context of allogeneic stem cell transplantation for the control of tumours has been rather disappointing 14, 20, 48, 49 . The failures of such strategies are most likely a consequence of the limited understanding of γδT cell receptor (γδTCR) diversity and the mode of action of receptor ligand interaction, along with current underestimation of the impact of functional diversity. However, substantial progress has been made recently towards providing new insights into receptor diversity, ligands ( fig. 2 ), repertoire focusing, functional diversity and plasticity ( fig. 3 ). The failure of clinical trials and novel molecular insights into receptor diversity and receptor-ligand interactions need to be considered in the design of future therapeutic concepts, to transform past failures into future successes, but not all currently recruiting trials are incorporating these novel insights in their designs ( Table 2 ).
Diversity of the γδTCR repertoire
A first step towards a better-defined and more effective cellular product derived from γδT cells and their receptors is to understand that each individual γδT cell that develops must undergo somatic recombination of its TRG and TRD gene loci so as to generate a functional γδTCR surface receptor. These heterodimers, which consist of one TCRγ and one TCRδ chain, are assembled via recombination of the variable (V), diversity (D) and joining (J) gene segments (VDJ recombination) of the TRD locus and, similarly, recombination of the V and J gene segments (VJ recombination) of the TRG locus. Thus, each γδT cell produces a unique 'clonal' γδTCR that assembles with CD3 proteins on the cell surface of γδT cells to transduce activating signals into the cell. These signals are required for proper survival and selection in the thymus, and they induce clonal γδT cell proliferation in response to peripheral stimulation. Consequently, the TCR repertoire of γδT cells in peripheral blood or within tumours is biased to over-represent those TCRs that can transduce a specific signal in response to encountering cognate antigenic ligands. Although the nature of specific γδTCR antigens remains largely elusive (see below), the variable and putative ligand-binding regions of γδTCRs are structurally more similar to the immunoglobulin domains of antibodies than to αβTCRs 50 , consistent with the notion that γδTCRs recognize surface antigens rather than MHC-presented peptides, as αβT-CRs do 51 . The potential number of possible TRD gene rearrangements is of the order of 10 13 (owing to multiple D segment usage during VDJ recombination), and the hypothetical total γδTCR diversity is in the region of 10 17 (10 13 multiplied by the additional diversity of >10 4 pairing TRG genes) 52 . Despite this extreme theoretical variety of the γδTCR repertoire, a large proportion of human and mouse γδT cells belong to a limited number of somewhat invariant T cell popu lations, which are typically delineated by the type of the specific Vγ segment used for Trg rearrangements in mice, and by the type of Vδ segments used for TRD rearrange ments in humans. Actually, most of the circulating γδT cells in humans are oligoclonal and use the same Vγ and Vδ gene segments -namely, Vγ9 and Vδ2 -with limited junctional diversity 53 . Moreover, a large fraction of these semi-invariant Vγ9Vδ2 T cells -which use a single, identical straight germline TRG rearrangement of Vγ9 and JγP without the typical additional nucleotide insertions at the V-J junction ALWEVQELGKKIKVare shared between all humans and cover several per cent of all TRG sequences in blood 54, 55 . Notably, most of the Vγ9Vδ2 T cells that carry TCRs composed of such canonical and similar Vγ9JγP variants are generated before birth and expand during the first years of life 56 . This is thought to be a consequence of microbial encounter and greatly contributes to the focusing of an oligoclonal Vγ9Vδ2 T cell repertoire in most individuals 57, 58 . However, such focusing still results in quite a substantial diversity of Vγ9Vδ2 T cells, which can be functionally important, as different γδTCR combinations have been reported to associate with different functional avidities 59 and with the ability to react to tumour cells treated with different agonistic or antagonist antibodies directed against CD277 (also known as butyrophilin-3A1 (BTN3A1)) and that also recognize BTN3A2 and BTN3A3 (ref. 60 ). In line with this assumption, polyclonal Vγ9Vδ2 T cell repertoires have been reported to be functionally inferior to cells that express a single, highly active Vγ9Vδ2 TCR, in terms of cytokine secretion or killing capacity 59 . Low-and non-phosphoantigen-reactive Vγ9Vδ2 TCRs have been reported to associate with the use of Jγ segments other than JγP, or with amino acids in critical positions of CDR3 regions that are different from the established key residues for phosphoantigen reactivity, such as position 97 of the Vδ2 chain 61, 62 . The targets of non-phosphoantigen-reactive Vγ9Vδ2 TCRs remain to be defined. Aside from the semi-invariant Vγ9Vδ2 T cells that dominate the peripheral γδTCR repertoire in most but not all humans, all the other clones are often perceived as non-Vγ9Vδ2 γδT cells. These comprise a plethora of unique rearrangements of Vδ1 and Vδ3,4,5,6,7,8 pairings with diverse TRG segments (Vγ2,3,4,5,8, and non-invariant Vγ9) and can adopt highly individual adaptive, yet unconventional, forms of immune surveillance at some point after birth 54, 63, 64 . This means that external stimulating signals, in particular CMV 16, 65, 66 , can drive a massive oligoclonal expansion of individual clones 16, 54, 57, 63, 67 . Thereby, each adult human exhibits a highly individualized oligoclonal γδT cell repertoire that can be regarded as a 'log file' that records environmental cues. Thus, all individuals have different polyclonal γδT cell repertoires driven by a unique history of infection, and most likely targeting different ligands 68 , which explains why the transfer of polyclonal non-Vγ9Vδ2 γδT cells would result in very diverse and difficultto-control products, which critically depend on the repertoire of each individual donor. This assumption also clarifies the varying outcomes after allogeneic stem cell transplantation in terms of leukaemia control and the control of infections, even when γδT reconstitution is pronounced 19 .
Furthermore, several subsets of human and mouse γδT cell repertoires are highly organ-specific 69 , especially intraepithelial γδT cells. Similar to the semiinvariant Vγ9Vδ2 T cells, intraepithelial γδT cells often display a restricted usage of Vγ segments, but very diverse δ chains. Prominent examples are the Vγ7 + and Vγ4 + γδT cells that dominate mouse and human intestinal epithelia, respectively 70 . Such a dichotomy of semi-invariant (public) γ chains pairing with a broad (private) repertoire of δ chains may be explained by results that have demonstrated that the organ specificity of certain γδTCRs is achieved by positive selection of germline-encoded regions in the lateral part of the γ chain, whereas the spatially distinct variable region that determines complementarity retains diverse antigen specificity 71 . Indeed, epithelia express the corresponding agonist-selecting factors, such as butyrophilin-like molecules, to shape organ-specific γδT cell compartments 72 .
Non-Vγ9Vδ2 TCR Using cells from compartments such as the skin for adoptive transfer could therefore be hampered not only by the diversity, but also by different homing properties 73 inherently linked to the nature of the γδTCR.
Cancer cell recognition
Our understanding of how γδT cells recognize tumour cells has lagged far behind the description of their receptor diversity. The main reason for this limited knowledge is the rather low affinity of many γδTCRs 59 , which frequently does not allow ligands to be identified through classical biochemical methods. In addition, γδTCRs are most likely part of a complex mechanism of recognition that involves more than one ligand on the tumour target 25, 74 , as well as the sensation of spatial and conformational changes through the γδTCR and potentially associated molecules. This mode of sensing molecules most likely allows cross-reactivity with multiple ligands by one defined γδTCR 25, 71, 75 . Nevertheless, even though they are limited, the findings on γδTCR antigen identification have led to development of the general concept that γδT cells are able to distinguish metabolic changes that discriminate normal cells from transformed cells, by recognizing stress-induced selfantigens. The ability of γδT cells to sense early changes of cells becoming tumour cells puts γδT cells in the first line of cancer immune surveillance, when few mutations have been acquired but initial metabolic changes have already occurred 76 . The repertoire itself, however, is shaped not by tumours but by other environmental factors (Table 3 ). This potential feature makes γδT cells and their receptors highly interesting additions to the currently available immune therapy strategies, but it also indicates that the simple transfer of polyclonal populations involves the risk of substantial diversity, and therefore a lack of activity. If properly activated, in vivo γδT cells and their receptors can sense tumours with low mutational loads, in contrast to many other immune therapies, such as checkpoint inhibitors 77 , and are therefore able to attack cells early in their transformation 5 and leukaemic stem cells 75 .
Vγ9Vδ2 T cells.
The oldest contribution to this concept was the demonstration that γδTCR-dependent recognition of tumour cells by human Vγ9Vδ2 T cells depends on a greater intracellular abundance within tumour cells of isopentenyl pyrophosphate (IPP, which belongs to the group of phosphoantigens), generated by overstimulation of the mevalonate pathway 78, 79 . Intracellular accumulation of IPP and subsequent tumour cell recognition by Vγ9Vδ2 T cells can be intentionally exacerbated in the presence of aminobisphosphonates, which are potent inhibitors of farnesyl pyrophosphate synthase, an IPP-downstream enzyme of the mevalonate pathway, and have been reported to generate variants of IPP on tumour cells 26, 80 . Which 'variant' of IPP constitutes the major natural biologically active molecule remains to be determined. As nucleotide derivatives are potentially more stable than naturally occurring phosphoantigensbecause the nucleotide group protects the functionally critical phosphate groups from broad phosphatase activities -they could turn out to be of greater interest for clinical applications. However, simulating a natural Vγ9Vδ2 T cell repertoire with a more stable IPP derivative could also mobilize mainly Vγ9Vδ2 T cells with TCRs of lower affinity, and therefore with less therapeutic value. It is also noteworthy that IPP released by an aminobisphosphonate-treated tumour cell can also act as a chemotactic molecule on Vγ9Vδ2 T cells 81 , a function that could help the homing of γδT cells into the tumour, even though this has yet to be confirmed in in vivo tumour settings. The molecular mechanisms underpinning Vγ9Vδ2 T cell activation by phosphoantigens has remained a matter of speculation for a long time. The small size of these compounds precludes direct TCR activation, and the understanding of how they allow Vγ9Vδ2 T cells to recognize tumour cells is still controversial. It is known that CD277, a ubiquitously expressed cell surface molecule, is implicated in this process 82 . Therefore, additional mechanisms must occur with or around CD277 that distinguish a healthy cell from a tumour cell. CD277 belongs to the B7 superfamily, and its interaction with phosphoantigens is mandatory for Vγ9Vδ2 TCR-dependent recognition of tumour cells. The exact framework of these interactions is still under debate 25, 83 . The current understanding supports the hypothesis of 'inside-out signalling' , in which CD277 undergoes secondary alterations once IPP levels are increased, such as joint spatial and conformational changes (CD277J) 75, 84 that are driven by the binding of phosphoantigens to the B30.2 intracellular domain of CD277 and to the CD277 juxtamembrane domain 85, 86 .
Assembly of the partner cytoskeletal molecules periplakin 87 and CD277 is most likely mediated by the small GTPase RhoB 75 . In addition, binding of CD277 to other members of the BTNA family, BTN3A2 and BTN3A3, is essential for the export of CD277 from the endoplasmic reticulum to the cell surface and the generation of a functional complex 88 . Most recently, it has also been proposed that CD277 and the Vγ9Vδ2 TCR do not interact directly with each other but form a complex in which each receptor has its individual ligand (two receptor-two ligand complex). In line with this assumption, other ligands have been proposed for the Vγ9Vδ2 TCR, which could, however, also reflect a potential cross-reactivity of the selected Vγ9Vδ2 TCR, as has been suggested for other γδTCRs 71 . These ligands include the complex comprising apolipoprotein AI and ecto-F1-ATPase as well as MutS homologue 2 (MSH2), which is reported to translocate to the cell membrane after oxidative stress or Epstein-Barr virus (EBV) transformation [89] [90] [91] . Chaperonin-containing T-complex allo-SCT, allogeneic stem cell transplantation; DC-CIK , professional antigen-presenting dendritic cells and cytokine-induced killer cells; EAGD T cell, expanded/activated γδT cells; TEG, T cells engineered to express a defined γδT cell receptor ; ZOL , zoldronate.
protein 1 subunit ζ (CCT6A), has been suggested as a potential self-antigen 92 when using Vδ2 CDR3-derived peptides as a screening tool, but because these do not fully mimic the structural loop of the Vδ2 TCR chain and miss the corresponding Vγ chain, their validity remains under debate.
Non-Vγ9Vδ2 T cells. Recognition of BTNL molecules by
γδT cells seems a broadly conserved mechanism shared by non-Vγ9Vδ2 T cell subtypes as well, in humans and in mice. Human intestinal Vγ4 γδT cells respond to the association of BTNL3 and BTNL8 expressed on enterocytes, whereas mouse intestinal Vγ7 γδT cells respond to the association of BNL1 and BTNL6 (ref. 72 ). Likewise, the development of epidermal Vγ5Vδ1 cells depends on the selection and upkeep of intraepithelial T cell protein 1 (SKIT1, another BTNL protein expressed by thymic epithelial cells and by keratinocytes) 93 . Interestingly, responsiveness to BTNL heterodimers is mediated by germline-encoded motifs in the human Vγ4 and mouse Vγ7 region of the TCRs that is independent of the binding of antigens to clonally restricted regions of these TCRs 93 . However, whether the Vγ4 γδT cells selected by BTN molecules are involved in response to tumours still requires further investigation. Given their much higher TCR repertoire diversity, non-Vγ9Vδ2 T cells are expected to recognize a broader range of antigens than Vγ9Vδ2 T cells. Indeed, the antigens identified so far have been varied and of strikingly different structures, suggesting a mode of recognition closer to that of immunoglobulins (for recent reviews [94] [95] [96] ). An increasing body of evidence suggests that the surface glycoprotein CD1 in complex with endogenous lipids may represent a very significant proportion of non-Vγ9Vδ2 T cell reactivities 97 . Yet, among this list of targets, few ligands may be involved in tumour cell recognition by γδT cells. The probably most comprehensive γδTCR ligand characterization for human γδT cells has been provided for the recognition of CD1d by a small population of circulating Vδ1 + γδT cells 98, 99 , and probably also by some Vδ3 + γδT cells 100 . Crystal structures of Vδ1 + TCR-CD1d complexes have revealed that the recognition of CD1d, a molecule usually involved in presenting lipids to natural killer T cells (NKT cells), is dominated by the Vδ1 chain, and that the lipid moiety is not necessarily involved in the interaction 97 (fig. 1c ). No evidence of CD1d implication in tumour cell recognition by Vδ1 + γδT cells has been reported so far, but the hypothesis that specific lipids could be presented to Vδ1 + γδT cells upon epithelial cell transformation deserves to be investigated. For NKT cells, CD1c-restricted recognition of defined tumour-specific lipids expressed on myeloid leukaemic cells has been described through the αβTCR of NKT cells 101 . As γδT cells are also able to recognize CD1a and CD1c-restricted targets 102, 103 , it is likely that other CD1-restricted γδT cells can also participate in cancer immune surveillance of haematological malignancies, although this has not yet been formally proved. Historically, the first tumour-associated cognate non-Vγ9Vδ2 γδTCR antigen reported was MHC class I-related chain A (MICA), which is overexpressed in carcinoma cells and recognized by tumour-infiltrating Vδ1 + γδT cells 104 . However, the contribution of the γδTCR in Vδ1 T cell activation by MICA-expressing cells is difficult to evaluate because NKG2D, a well-known highaffinity receptor for MICA, is also expressed on most γδT cells. Moreover, the original report of Vδ1 TCRmediated activation by MICA 104 has been strongly challenged by Luoma et al. 99 . This study showed that one of the original TCRs described as MICA-reactive (δ1A/B-3) displayed a much higher affinity for a CD1d-sulfatide complex than for MICA. Thus, the proposed reactivity of Vδ1 TCRs to MICA may in fact be limited to crossreactivity of some CD1d-restricted TCRs, perhaps a side effect of the relatively high degree of homology between CD1d and MICA. Another MHC-I-related molecule overexpressed on carcinoma cells and documented as being a direct ligand of a Vγ4Vδ5 TCR is the endothelial protein C receptor (EPCR) 105 . Even if EPCR, like CD1d, is able to bind phospholipids, the Vγ4Vδ5 TCR can bind EPCR in a lipid-independent and antibody-like manner. The tumour antigens reported for non-Vγ9Vδ2 T cells are not always MHC-related molecules, such as annexin A2, a ubiquitously expressed intracytoplasmic Ca2 + -dependent phospholipid binding protein. This protein exemplifies what we can expect from a genuine γδTCR stress antigen. Annexin A2 can be presented on the cell surface upon oxidative stress-induced translocation, and its expression is enhanced in many cancers, in which it is associated with a histological grade of the disease 106 . Annexin A2 was found to activate Vδ1 and Vδ3 T cell clones, and molecular binding to a Vγ8Vδ3 TCR was demonstrated 107 .
In addition to γδTCR antigens, tumour cells can express many other ligands that participate in the activation of γδT cells by tumour cells, which are usually also expressed on NK cells 18 . Ligands of activating receptors such as NKG2D and DNAX accessory molecule 1 (DNAM1) are important contributors to the activation of γδT cells (for a review 95 ). Many tumours, indeed, express various amounts of the NKG2D ligands MICA and MICB, or UL16 binding protein (ULBP), or the DNAM1 ligands, nectin-2 and polyoma virus receptor (PVR). The natural cytotoxicity receptors NKp30 and NKp44 can also be induced in vitro on the surface of Vδ1 + γδT cells, when activated through the γδTCR in the presence of cytokines 108 . These receptors confer a stronger reactivity against leukaemia cells to Vδ1 + γδT cells. Another mechanism of tumour recognition could involve MHC-I downregulation, which is frequently observed in tumours that escape surveillance by conventional αβT cells. This immune evasion process is not expected to prevent response by MHC-I-independent γδT cells, and it can even promote their response through the consecutive activation of natural killer inhibitory receptors (KIRs, also known as killer cell immunoglobulin-like receptors or leukocyte immunoglobulin-like receptors (LIRs)), which are widely expressed on γδT cells 109, 110 . 109, 111 . Likewise, the KIR system of γδT cells is, during cancer progression, most likely the functional downfall of γδT cells, as rapid tolerance of γδT cells has been described in patients with advanced-stage cancer 27 , and KIR-like receptors, which are most likely involved in the education of γδT cells, have also been observed in NK cells 112 . The impact of the KIR system may be particularly relevant when γδT cells are given as third-party cells, alone or with the infusion of haploidentical stem cell products, and can potentially enhance tumour reactivity, although thorough analyses are still missing 20 . Finally, on rare occasions γδTCRs have been reported to recognize classical tumourassociated antigens within classical HLA complexes, such as in αβT cells 113 . In allogeneic systems, γδTCRs are able to sense spatial and conformational changes in HLA 114 , which is potentially useful for haploidentical transplantations 20 or genetic-engineering strategies 115 .
Vγ9Vδ2 T cells are highly cytotoxic against MHC class-I-deficient B cell lines, such as Daudi cells, whereas lysis of MHC class I-positive tumour B cell lines by Vγ9Vδ2 T cells requires KIR inhibition

Functional diversity and tolerance
Human γδT cells are naturally biased towards a cytotoxic type 1 phenotype, which involves production of the antitumour cytokines IFNγ and TNF. In fact, newborns (including preterm babies) already harbour a sizeable population of circulating IFNγ-and TNF-positive γδT cells 116 . Type 1 differentiation seems to be the default pathway for naive human thymocytes, as it is promptly deployed upon IL-2 (or IL-15) stimulation 117 . However, the diversity of what seems to be pro-inflammatory γδT cells can be shaped by microbial encounter, through epigenetic regulation of gene expression that results in the preferential expansion of subclones and the functional alteration of γδT cells during ageing 67, 118 (fig. 3a) . Analyses of such effector cells at a clonal level in healthy individuals reveals a great heterogeneity of Vγ9Vδ2 T cell clones between different individuals, with, among other differences, high frequencies of Vγ9Vδ2 T clones that do not get activated by cancer cells (Z. S. & J. K., unpublished observations) ( fig. 3a) . A highly diverse Vγ9Vδ2 T cell repertoire, with many different functional profiles and affinities of individual receptors, provides an additional explanation as to why polyclonal in vitro expansion of Vγ9Vδ2 T cells followed by infusion into cancer patients has failed over decades in clinical studies.
Tumour encounter through γδT cells can result in anergy or the deletion of γδT cells. The expression of the potent immunosuppressive molecule programmed cell death ligand 1 (PDL1) and other checkpoint molecules by tumour cells most likely has a crucial role in this process 119 . Daley et al. explored the pro-tumoural role of γδT cells in pancreatic ductal carcinoma, in which the majority of tumour-infiltrating T cells are in fact γδT cells. In a murine model, depletion of γδT cells or PDL1 blockade restored CD4 + and CD8 + T cell infiltration and functionality, thus inhibiting tumour progression 119 . However, PDL1-based immunosuppression has yet to be established as a relevant pro-tumoural function of γδT cells in other cancer types. Inflammatory signals in the tumour microenvironment can also seemingly Cytotoxic type 1 phenotype ability in αβ and γδ T cells to mediate the killing of target cells through the secretion of granzymes and perforin. Such T cells usually also produce ifNγ and TNf.
Anergy
State of an immune cell, which correlates with loss of function and can also result in deletion, and thus the complete loss of defined γδT cells.
subvert this antitumour phenotype of γδT cells, 'reprogramming' them into regulatory γδT cells (T reg cells) 120, 121 ( fig. 3b ). An effector function that can clearly associate with tumour progression, rather than elimination, is the production of IL-17. A large body of research in mice has demonstrated that IL-17 + γδT cells can mobilize immunosuppressive and tumour-promoting myeloid cells 3 . For example, peritoneal IL-17 + γδT cells recruited pro-inflammatory and pro-angiogenic macrophages that promoted ovarian cancer progression 122 . A link between IL-17 + γδT cells and angiogenesis was also observed in several other transplantable models of cancer 123 . Importantly, the pro-tumoural function of IL-17 + γδT cells was also validated in spontaneous models of pancreatic 124 and breast cancer 125 . In the breast cancer model, crosstalk was suggested between γδT cells and neutrophils 125 . Human γδT cells are much less prone to produce IL-17 than are their murine counterparts, and IL-17 production is seemingly restricted to highly inflammatory contexts (rich in IL-1β and IL-23) driven by infections 126 or cancer 3 . Thus, IL-17 + γδT cells are associated with the recruitment of suppressive myeloid cells and metastasis in various cancer types, most notably CRC 9, 121 . Moreover, IL-17-producing versus IFNγ-producing γδT cells in tumour biopsy samples seem to have opposite prognostic values for cancer patients 120, 127 . The adoption of T reg cell-like functions that impair dendritic cell (DC) maturation and function is another tumour-promoting phenotype associated with tumour-infiltrating γδT cells [128] [129] [130] [131] .
These pro-tumoural roles notwithstanding, linking transcriptional analysis to clinical outcomes across many cancer entities seems to indicate an overt favourable pro gnostic value for tumour-infiltrating γδT cells 10 , which suggests the dominance of antitumour over protumour effector functions. The establishment of this paradigm requires further analyses at the protein level that will encompass γδT cell subsets and their effector signatures.
Clinical translation of novel approaches
On the basis of the described novel molecular mechanisms, alternative therapeutic strategies to treat cancers with γδT cells or extracted receptors from γδT cells have been developed, through both academia and commercial partners in the field (Table 4 ). These approaches are based on the principle of either recruiting still available γδT cells with approved drugs or overcoming polari zation towards a tolerogeneic profile by inducing the expression of activation molecules through defined in vitro stimulation methods followed by adoptive transfer. As such, stimulation methods associate only with temporary changes; alternatively, genetic engineering of γδT cells or the expression of defined tumour-reactive γδTCRs on the surface of αβT cells has been explored in order to overcome the functional constraints inherently linked to the nature of γδT cells ( fig. 4 ).
Novel strategies to recruit γδT cells
The recruitment of Vγ9Vδ2 T cells with aminobisphosphonates has not been successful in the past (Table 1) . Nevertheless, alternative strategies are currently being explored, including the selective recruitment of resident γδT cells with bispecific molecules that link γδT cells to endothelial growth factor receptor (EGFR)-expressing tumour cells through an anti-γδTCR-mediated moiety and an anti-EGFR antibody 132 . Whether this concept will be more effective than classical bispecific molecules that link all CD3-expressing cells (including both αβ and γδ T cells) to defined surface antigens expressed on tumours 133 remains to be tested, and the outcome relies on the observation that tumours are not always equally infiltrated with both αβ and γδ T cells 10 . Topical injection of genetically engineered chemo-resistant γδT cells for patients with glioblastoma has therefore been suggested in order to overcome the homing challenges of endogenous γδT cells and at the same time to allow the administration of standard chemotherapy 134 . An alternative strategy to support the effectiveness of endogenous γδT cells arises from the observation that ibrutinib, an inhibitor of BTK tyrosine kinase that is currently in use for the treatment of chronic lymphocytic leukaemia (CLL), can partially reverse the tolerance of Vγ9Vδ2 T cells to patient-derived CLL cells in vitro 135 . Whether this will indeed improve the fitness of γδT cells in patients for a longer time in vivo needs to be investigated in the future. In addition, checkpoint inhibitor treatment most likely also affects the tumour-reactive γδT cell repertoire. Patients treated with ipilimumab showed a higher proportion of endo genous Vγ9Vδ2 T cells but not of non-Vγ9Vδ2 γδT cells 136 , implying that the success of checkpoint inhibitor treatments does not depend solely on the tumour-reactive αβT cell repertoire. Surprisingly, this study showed diffe rent effects on the δ2 + and δ2 − γδT cell repertoires, with an increase in δ2 + γδT cells and a decrease in the frequency of δ2 − γδT cells over time, implying that the regulatory mechanisms differ substantially between the two subsets.
Vδ1-enriched γδT cells
Delta one T (DOT) cells are a Vδ1-enriched (>60%) γδT cell product for adoptive transfer, produced in a period of over 3 weeks under stimulation with TCR agonists and cytokines 108 . The protocol includes a δ1-biased expansion stage, based on stimulation with IL-4 and TCR agonists, and a differentiation stage that depends on the addition of IL-15. Coupled with large-scale (>1,000fold) expansion of the DOT cells, the DOT-cell protocol induces de novo expression of natural cytotoxicity receptors, particularly NKp30 and NKp44, while also upregulating the expression of NKG2D and DNAM1 (ref. 108 ). Thus, NK recognition mechanisms, tightly associated with their cytotoxic potency, are boosted selectively in DOT cells by the DOT-cell protocol. NKp30 and NKp44, previously thought to be NK-cell specific, seem to be of major relevance, as their ligation (via agonist antibodies) enhances tumour cell killing, whereas their antibodymediated blockade significantly reduces tumour cell targeting, especially when combined with anti-TCR monoclonal antibodies 108, 137 . Most recently, targeting of acute myeloid leukaemia (AML) by DOT cells was reported to be strongly dependent on expression of the NKp30 ligand B7-H6 (ref. 138 ). However, which additional specific tumour ligands underlie DOT-cell reactivity Regulatory γδT cells (T reg cells). a subpopulation of T cells that modulate the immune system. Until recently regulatory cells have been attributed solely to αβT cells, and they are characterized by the expression of CD4, CD25 and fOXP3, with a subset also producing il-17. Now it has also been proposed that γδT cells have regulatory properties and that regulatory γδT cells secrete il-17 and mediate tolerance against cancer cells.
Tolerogeneic profile
immune cells secreting cytokines that induce tolerance, such as il-10 and il-17, or enhance the expression of inhibitory checkpoint molecules in their microenvironment.
Ipilimumab
Monoclonal antibody that activates immune cells by targeting CTla4. and the relative contributions of natural cytotoxicity receptors versus γδTCRs have not yet been established.
γδT cells expressing CARs
As the transfer of expanded and non-manipulated Vγ9Vδ2 T cells has been considered safe but also ineffec tive, γδT cells are currently being explored as carriers for chimeric antigen receptors (CARs) 139, 140 . As has also been suggested for NK cells as carriers, γδT cells hypothetically have a lower risk of mediating unwanted side effects, including cytokine release syndrome, which has also been reported to be less likely with NK cells as carriers 141 . However, both subpopulations are under tight control by natural cytotoxicity receptors and KIRs, and therefore might be educated over time 112 . Long-term persistence of adoptively transferred γδT cells could theoretically be a problem, as has again been reported for the transfer of NK cells which are under the regulatory control of comparable receptors 142 . In addition, this strategy does not resolve the urgent need to identify 
Cytokine release syndrome
Mild to life-threatening syndrome caused by a rapid release of cytokines after adoptive transfer of Car T cells or other types of immune therapy.
targets that do not depend on mutational load and are not exclusively expressed in haematological cancers, like CD19 (ref. 143 ).
T cells engineered with γδTCRs
Understanding the molecular needs of γδT cells and their receptors as they protect us from cancer has been key to partially overcoming the tolerance and deletion of natural γδT cells in many patients with advanced-stage disease 16, 18, 59, 68, 75, 144, 145 . These insights represent the beginning of a paradigm shift, which establishes that cancer can be targeted therapeutically as a metabolic disease through specifically defined receptors, and that disease control does not depend on the mutational load of cancers. This clinical concept combines our knowledge of targeting cancer through individual receptors expressed on γδT cells with the high proliferation and memory capacity of conventional αβT cells, and thereby bypasses the fact that γδT cells are frequently deleted in patients with advanced-stage disease, are proliferation-deficient or are turned into γδT cells that produce IL-17 and thereby contribute to the tolerance of cancer cells 125 . This concept of the next generation of CAR T cells, named T cells engineered with defined γδTCRs (TEGs) 59, 145, 146 , commercialized through a firstlead structure, has been acknowledged as a major breakthrough in the field 147 . TEGs -defined as αβT cells transduced with γδTCRs -enable selecting for the Vγ9Vδ2 TCR with the highest affinity 59 , or for δ2 − γδTCRs, and thereby can target a broad range of solid and haematological tumours 16 , leading to the next generation of personalized cancer care. By using Vγ9Vδ2 TCRs, TEGs can target leukaemic stem cells 75 and eliminate primary multiple myeloma in a 3D bone marrow niche 148 .
In addition, once a Vγ9Vδ2 TCR is expressed in an αβT cell, activating signalling through the γδTCR is less prone to inhibition by KIRs, owing to the lower abundance of such receptors on αβT cells than on γδT cells. If both CD4 + and CD8 + T cells are reprogrammed with a defined Vγ9Vδ2 TCR, not only are cytotoxic properties present, but CD4 + TEGs also have the ability to mature professional antigen-presenting cells, such as dendritic cells (DCs) 59 . Maturation of DCs is mediated by CD4 + TEGs that sense increased phosphoantigen levels on immature DCs in the presence of aminobisphosphonates through the γδTCR, as well as by the natural ability of CD4 + αβT cells to mature DCs in the presence of cognate antigens 145 . This property creates an additional opportunity for epitope spreading towards classical tumourassociated antigens. TEGs expressing a high-affinity Vγ9Vδ2 TCR 149 are currently being used in a phase I clinical trial in patients with relapsed and refractory AML and multiple myeloma 150 . This therapeutic strategy represents the tip of the iceberg of a myriad of potential strategies derived from γδT cells and their receptors 147 , as the diversity of individual receptors exceeds by 2-3 log the theoretical diversities of antibodies and αβTCRs 1 .
Efficacy and toxicity screens
When exploring novel cellular products derived from γδT cells and their receptors, translational challenges arise, owing to the mechanism of action of metabolic cancer targeting, which frequently is poorly characterized. Identifying those patient populations that have a high likelihood of clinical response before inclusion in clinical trials will be key to increasing the chances of success for such trials. In addition, safety issues, such as cross-reactivity to healthy tissues within the context of inflammation, for instance, need to be thoroughly addressed so as to avoid off-target effects -as have been observed, for example, in αβT cell engineering therapies 151 . For Vγ9Vδ2 TCR-based therapies, novel insights into the higher susceptibility of patients who harbour defined single-nucleotide polymorphisms or who show Depicted are three currently pursued therapeutic concepts. a | The first concept uses natural non-Vγ9Vδ2 γδT cells, which are forced through culture conditions to express the two tumour-reactive receptors NKp30 and NKp44. This first concept has the downside of the potential downregulation of these naturally expressed receptors once the cells are infused into a patient. b | To overcome this, a second concept was designed that forces the expression of tumour-reactive chimeric antigen receptor (CAR) γδT cells. In contrast to concept a, this concept usually uses Vγ9Vδ2 γδT cells as carriers, owing to their higher abundance in the peripheral blood and easier access for in vitro engineering, and results in long-term expression of these novel introduced receptors. c | The third concept takes advantage of tumourreactive γδT cell receptors (γδTCRs), which can be isolated from either non-Vγ9Vδ2 or Vγ9Vδ2 γδT cells. γδTCRs recognize tumours through more primitive mechanisms and therefore are applicable to a broad patient population. By taking advantage of αβT cells as carriers, researchers can engineer T helper and T effector cells to generate the basis for a long-lasting immune response. In addition, this concept outcompetes endogenous αβTCRs through the forced genetic expression of γδTCRs, and thereby eliminates the classical allo-reactivity of engineered αβT cells. DOT cells, δ1 T cells; TEGs, T cells engineered with γδTCRs. re-localization of the small GTPase RhoB from the nucleus or the nuclear membrane to extranuclear sites might assist in narrowing down patient populations if these characteristics are used as biomarkers. Analysing liquid biopsy samples for this typical pattern of RhoB localization in cancer cells could become a mandatory inclusion criterion for patients 75 . However, these options are unlikely to predict with precision the spatial and conformational changes of CD277J, the target needed for recognition. Also, for receptors that target EPCR 74 , the expression of EPCR alone is not sufficient to explain recognition through the γδTCR. Therefore, additional molecular insights are urgently needed in order to further increase the chance of success of clinical trials. However, this limited knowledge should not hamper the initiation of future clinical trials. As we have learned from agents such as tyrosine kinase inhibitors 152 or CD38-targeting agents 153 , limited understanding regarding specificity or secondary immune modulatory effects during the first clinical tests was later part of the trials' clinical success, as the true mechanism of action frequently seems to be broader than was initially anticipated. In the case of targeting CD38, both direct targeting of the cancer cell through anti-CD38 antibodies and multiple immunemodulating effects on different immune subsets seem to be required for mediating full efficacy 154 .
A major concern for safety when using γδT cells and their receptors is that the early metabolic changes in cancer cells sensed through γδT cells might also occur in healthy tissues or after stress situations, although no causal relation between γδT cell infiltration and autoimmunity has been described in humans. However, associations between the presence of γδT cells and inflammatory processes have been described in, for example, patients with inflammatory bowel disease 155 . Therefore, appropriate efficacy and safety tests need to be developed to allow a progression to clinical trials.
A challenge arises from the evolutionary divergence between rodents and primates in the genes encoding TCRγ and TCRδ 96 , which makes syngeneic models of cancer particularly limited to providing proof of concept for γδT cell-based immunotherapies. Therefore, most preclinical in vivo studies have been carried out with xenograft models, in which human tumour cell lines or primary tumour samples are injected into immunodeficient (such as NOD scid γ (NSG)) mice 3, 138, 148, 156 . The proof of concept has been obtained in xenograft models of chronic lymphocytic leukaemia and acute myeloid leukaemia 108, 137 . In all of these studies, DOT-cell treatment significantly reduced tumour burden, prevented systemic dissemination in a subcutaneous CLL model, and increased host survival. Histology analysis of multiple tissues and biochemical tests for liver and kidney function revealed no undesirable side effects of DOTcell treatment. However, xenograft models have important limitations for toxicology evaluation, as they do not express the natural targets of the receptors expressed on γδT cells, and therefore cannot assess on-and off-target effects. TEG therapies have had similar challenges, and we can learn from the successful clinical trial approval of TEGs by Dutch authorities 150 . Owing to the lack of staining tools to directly assess CD277J expression on healthy and diseased tissues 25, 75 , extensive ex vivo testing for efficacy and toxicity against haematological healthy tissues and tumours was initiated 59, 145, 149 . To overcome the limitation that not all haematopoietic tissues could be tested, engraftment of primary acute myeloid leukaemia and healthy cord blood in NSG mice allowed for confirmation of the selective targeting activity against primary acute myeloid leukaemia, while not harming any other outgrowth of normal haematopoiesis 156 .
Investigating the activity of TEGs against normal solid tissues ex vivo is complicated by the observation that the culturing and expansion of healthy solid tissues frequently results in recognition by natural Vγ9Vδ2 T cells (J. K., unpublished observation). This observation implies a physiological role for Vγ9Vδ2 T cells in sensing proliferation in solid tissues 157 , which is an early hallmark of cancer, regardless of mutational load. This favourable biological feature of Vγ9Vδ2 T cells and their Vγ9Vδ2 TCRs at first sight makes them impossible to test in a broader range of solid tissues ex vivo, and substantially complicates safety tests. Furthermore, we have observed multiple acquired chromosomal aberrations, such as deletions and duplications, in cultured and proliferating healthy non-haematopoietic tissues, as have also been reported for healthy organoids after long-term culture 156, 158 . Therefore, non-human primates (NHPs) represent an alternative in vivo model for toxicology studies, despite their almost prohibitive costs, questionable added value and the related ethical concerns. In the γδT cell field, primates have been successfully used to study the therapeutic potential of Vγ9Vδ2 T cells in tuberculosis 159, 160 . However, there are various challenges when using NHPs to evaluate the toxicology of γδT cell products for cancer immunotherapy. First, in an exclusive macaque setting, it is very difficult to guarantee the validity of conclusions with a comparable cellular product, particularly conclusions concerning toxicity. For example, some of the key receptors expressed on human DOT cells are considerably different from those in macaques, as exemplified by the observation that NKp44 is only a pseudogene in NHPs 161 . Secondly, simply carrying out such studies involves a number of difficulties. In a monkey xenograft setting for human γδT cell products, for instance, there is a need for cross-reactivity of the key homeostatic cytokines (such as IL-7 and IL-15), for sustainability; likewise, ethical issues arise when the presence of tumours is required in order to provide signals for γδT cell persistence in vivo; and finally, the potential need for immunosuppression of the host, to allow full acceptance of the human graft, may defeat the purpose of the experiment.
On the basis of these considerations, we believe that the best available strategy is to complement in vivo xenograft models with in vitro assays using co-cultures that evaluate cellular crosstalk, cytokine release and cytotoxicity among exclusively human components. One example is a 3D bone marrow niche model that allows for assessment of the selective activity of TEGs against primary multiple myeloma cells and the surrounding healthy stroma 148 . For solid tumours, opportunities arise through the ability to culture healthy organoids, such as from colon tissues, as well as tumour tissues 162 , and to co-culture tumouroids and organoids with immune cells 163 .
Outlook and future perspective The success of many immune therapies has resulted from the precise understanding of receptor-ligand interactions, such as the characterization of TCR-MHC recognition, as well as from checkpoint targeting (such as PD1-PDL1) 164 . To rationally exploit γδT cells and their receptors for cancer immune therapies, it is therefore necessary to reveal their receptor diversity and cognate ligands. If one assumes that tumour-reactive γδT cells become activated and proliferate when their γδTCR recognizes specific signals emanating from transformed cells, then monitoring of γδTCR repertoires at the molecular level will be instructive for the identification of novel tumour-reactive γδTCR vari ants and for subsequent identification of their cognate tumour-related antigens.
Thus, only once investigators finally understand the impact that different CDR3 regions of the Vγ9Vδ2 TCR have on the functional consequences regarding different ligands and epi genetic regulation, including the regulatory mechanism for each individual subset, will γδT cellbased therapies have a chance to reveal their true power. Also, homing or local stimulation factors that are inherently linked to defined Vγ chains will need to be taken into consideration, as well as novel efficacy and safety testing models, in order to rapidly screen for potentially successful compounds. As multiple γδT cell-based therapies have recently been successfully evaluated for efficacy and toxicity, production processes have been developed according to good manufacturing practice 108, 146, 149 , and a new generation of clinical trials is currently evolving to test these novel concepts ( fig. 4 ; Table 2 ).
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